1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Califf Touches On A Range Of Issues And Priorities During Fireside Chat

 
• By Brian Bossetta

During a recent webinar hosted by the Alliance for a Stronger FDA, commissioner Robert Califf discussed the agency’s 2024 budget, its ongoing reorganization, AI, LDTs, and the continuing problem of misinformation.

FDA Shadow
• Source: Shutterstock

As he nears the end of the second year of his second stint leading the US Food and Drug Administration, one of the top priorities facing commissioner Robert Califf is the agency’s ongoing reorganization — the “biggest in the agency’s history” — which, Califf said, “will fundamentally change the way that we work.”

Califf discussed the reorganization, along with other topics of concern, during a webinar on 31 January hosted by the Alliance...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Regulation

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

 
• By Elizabeth Orr

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 
• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

Commission Decision Launches Pediatric And Rare Disease Expert Group

 
• By Amanda Maxwell

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.

More from Policy & Regulation

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 
• By Malcolm Spicer

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 
• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Commission Decision Launches Pediatric And Rare Disease Expert Group

 
• By Amanda Maxwell

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.